Acorah Software Products - Accounts Production 18.1.200 false true 31 March 2025 1 April 2024 false 1 April 2025 31 March 2026 31 March 2026 11657705 Dr RC Knights iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 11657705 2025-03-31 11657705 2026-03-31 11657705 2025-04-01 2026-03-31 11657705 frs-core:CurrentFinancialInstruments 2026-03-31 11657705 frs-core:RevaluationReserve 2025-04-01 2026-03-31 11657705 frs-core:RevaluationReserve 2025-03-31 11657705 frs-core:RevaluationReserve 2026-03-31 11657705 frs-core:ShareCapital 2026-03-31 11657705 frs-core:RetainedEarningsAccumulatedLosses 2025-04-01 2026-03-31 11657705 frs-core:RetainedEarningsAccumulatedLosses frs-core:PreviouslyStatedAmount 2025-03-31 11657705 frs-core:RetainedEarningsAccumulatedLosses 2026-03-31 11657705 frs-bus:PrivateLimitedCompanyLtd 2025-04-01 2026-03-31 11657705 frs-bus:FilletedAccounts 2025-04-01 2026-03-31 11657705 frs-bus:SmallEntities 2025-04-01 2026-03-31 11657705 frs-bus:AuditExempt-NoAccountantsReport 2025-04-01 2026-03-31 11657705 frs-bus:SmallCompaniesRegimeForAccounts 2025-04-01 2026-03-31 11657705 frs-core:UnlistedNon-exchangeTraded 2026-03-31 11657705 frs-core:UnlistedNon-exchangeTraded 2025-03-31 11657705 frs-core:CostValuation frs-core:UnlistedNon-exchangeTraded 2025-03-31 11657705 frs-core:AdditionsToInvestments frs-core:UnlistedNon-exchangeTraded 2026-03-31 11657705 frs-core:DisposalsRepaymentsInvestments frs-core:UnlistedNon-exchangeTraded 2026-03-31 11657705 frs-core:RevaluationsIncreaseDecreaseInInvestments frs-core:UnlistedNon-exchangeTraded 2026-03-31 11657705 frs-core:CostValuation frs-core:UnlistedNon-exchangeTraded 2026-03-31 11657705 frs-core:ProvisionsForImpairmentInvestments frs-core:UnlistedNon-exchangeTraded 2025-03-31 11657705 frs-core:ProvisionsForImpairmentInvestments frs-core:UnlistedNon-exchangeTraded 2026-03-31 11657705 frs-bus:Director1 2025-04-01 2026-03-31 11657705 frs-countries:EnglandWales 2025-04-01 2026-03-31 11657705 2024-03-31 11657705 2025-03-31 11657705 2024-04-01 2025-03-31 11657705 frs-core:CurrentFinancialInstruments 2025-03-31 11657705 frs-core:RevaluationReserve 2025-03-31 11657705 frs-core:ShareCapital 2025-03-31 11657705 frs-core:RetainedEarningsAccumulatedLosses 2025-03-31
Registered number: 11657705
RCK (Pathology) Ltd
Unaudited Financial Statements
For The Year Ended 31 March 2026
RCK (Pathology) Ltd
Contents
Contents

| Page
--- | ---
Balance Sheet | 1—2
Notes to the Financial Statements | 3—4

Page 1
RCK (Pathology) Ltd
Balance Sheet
As At 31 March 2026
Balance Sheet
Registered number: 11657705

| 2026 | 2025
--- | --- | ---
| Notes | £ | £ | £ | £
FIXED ASSETS
Investments | 4 |  | 52,931 |  | 49,998
|  |  | 52,931 |  | 49,998
CURRENT ASSETS
Cash at bank and in hand |  | 472,422 |  | 395,670 |
|  | 472,422 |  | 395,670 |
Creditors: Amounts Falling Due Within One Year | 5 | (31,221 ) |  | (36,233 ) |
NET CURRENT ASSETS (LIABILITIES) |  |  | 441,201 |  | 359,437
TOTAL ASSETS LESS CURRENT LIABILITIES |  |  | 494,132 |  | 409,435
NET ASSETS |  |  | 494,132 |  | 409,435
CAPITAL AND RESERVES
Called up share capital | 6 |  | 100 |  | 100
Revaluation reserve | 7 |  | 3,451 |  | (9 )
Profit and Loss Account |  |  | 490,581 |  | 409,344
SHAREHOLDERS' FUNDS |  |  | 494,132 |  | 409,435

Page 1
Page 2
RCK (Pathology) Ltd
Balance Sheet (continued)
As At 31 March 2026
For the year ending 31 March 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The member has not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.
On behalf of the board

Dr RC Knights Director
15/04/2026

The notes on pages 3 to 4 form part of these financial statements.
Page 2
Page 3
RCK (Pathology) Ltd
Notes to the Financial Statements
For The Year Ended 31 March 2026
Notes to the Financial Statements
1. General Information
RCK (Pathology) Ltd is a private company, limited by shares, incorporated in England & Wales, registered number 11657705 . The registered office is Old Yew Cottage, Royd Lane, Holmfirth, HD9 2JA.
2. Accounting Policies
2.1. Basis of Preparation of Financial Statements
The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.
2.2. Turnover
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover is reduced for estimated customer returns, rebates and other similar allowances.
3. Average Number of Employees
Average number of employees, including directors, during the year was: NIL (2025: NIL)
- -
4. Investments

| Unlisted
--- | ---
| £
Cost or Valuation
As at 1 April 2025 | 49,998
Additions | 1
Disposals | (527 )
Revaluations | 3,459
As at 31 March 2026 | 52,931
Provision
As at 1 April 2025 | -
As at 31 March 2026 | -
Net Book Value
As at 31 March 2026 | 52,931
As at 1 April 2025 | 49,998

5. Creditors: Amounts Falling Due Within One Year

| 2026 |  | 2025
--- | --- | --- | ---
| £ |  | £
Corporation tax | 24,368 |  | 24,385
Accruals and deferred income | 882 |  | 876
Director's loan account | 5,971 |  | 10,972
| 31,221 |  | 36,233

6. Share Capital

| 2026 |  | 2025
--- | --- | --- | ---
| £ |  | £
Allotted, Called up and fully paid | 100 |  | 100

Page 3
Page 4
RCK (Pathology) Ltd
Notes to the Financial Statements (continued)
For The Year Ended 31 March 2026
7. Reserves

| Revaluation reserve | Profit and Loss Account
--- | --- | ---
| £ | £
As at 1 April 2025 | (9 ) | 409,344
Profit for the year and total comprehensive income | - | 85,197
Dividends paid | - | (500)
Transfer from revaluation reserve | - | (3,460)
Transfer to/from Profit & Loss Account | 3,460 | -
As at 31 March 2026 | 3,451 | 490,581

Page 4